Stem Cell Clinic

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that on November 1, 2024, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase an aggregate of 6,500 shares of the Company’s common stock. The shares underlying the employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to the employee’s continued employment with the Company on such vesting dates. The above-described award was made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).

More here:
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

By Global News Feed

PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of incorporation with the Secretary of State of the State of Delaware. The Company expects that its common stock will begin trading on a split-adjusted basis when the market opens on November 8, 2024, under its current trading symbol “LIPO.” Following the reverse stock split, the CUSIP number for the Company’s common stock will be updated to 53630L209.

Originally posted here:
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

By Global News Feed

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third parties.

Original post:
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

By Global News Feed

TORONTO and HAIFA, Israel, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce, further to its press release dated September 26, 2024 (the “September 26 Release”), the closing of the final tranche of its previously announced non-brokered private placement (the “Offering”) for gross proceeds of $127,499.90 (“Tranche 2”). In the Offering, the Company raised aggregate gross proceeds of $1,737,647.45 through the issuance of 3,159,359 Units. Capitalized terms not otherwise defined herein have the meanings attributed to them in the September 26 Release.

See the rest here:
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer…

By Global News Feed

Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers

Visit link:
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer...

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

By Global News Feed

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 651,380 ordinary shares of the Company originally issued in April 2024, at an exercise price of US$44.14 per share. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately US$28.75 million. The Company intends to use the net proceeds from the offering for general corporate purposes.

More here:
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

By Global News Feed

MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialized diagnostic radiopharmaceuticals1 for Medicare Fee for Service patients in the hospital outpatient setting, beyond the transitional pass-through payment period (“pass-through”). This is a significant decision for patients and hospitals, with the change facilitating equitable access to advanced imaging agents for all patients into the future.

Follow this link:
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for…

By Global News Feed

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

Continued here:
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for...

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

By Global News Feed

QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat?Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion // QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring fast and accurate results to support clinical decision-making QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successful expansion of QIAstat?Dx tests developed specifically for the U.S. // QIAGEN now offers broad menu with FDA-cleared tests for respiratory, gastrointestinal and central nervous system infections – and plans for further expansion // QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring fast and accurate results to support clinical decision-making

View original post here:
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

→←